Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Inclusion Criteria: * Infection with HCV * Must have participated in a prior Gilead HCV study * Use of highly effective contraception methods if female of childbearing potential or sexually active male * Eligible patients include those in the following * received placebo or Peg-IFN+RBV in a control arm * previously participated in a Gilead-sponsored HCV study and did not attain sustained virologic response 24 weeks after discontinuation of therapy (SVR24) on a regimen containing: * Sofosbuvir+RBV * Peg-IFN and/or RBV in combination with one or more Gilead investigational direct-acting agents Exclusion Criteria: * Pregnant or nursing female or male with pregnant female partner * Current or prior history of clinical hepatic decompensation * Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) * Chronic use of systemically administered immunosuppressive agents * Active drug abuse * Use of any prohibited concomitant medications